Varda releases results of its in-orbit test for producing pharmaceuticals in weightlessness
On March 20, 2024 Varda released the results from its seven-month-long flight of its unmanned capsule, claiming that the technology worked to produce pharmaceuticals in weightlessness that will be better at treating some difficult illnesses such as HIV.
From the abstract of the preprint paper [pdf]:
Despite notable progress in realizing the benefits of microgravity, the physical stability of therapeutics processed in space has not been sufficiently investigated. Environmental factors including vibration, acceleration, radiation, and temperature, if not addressed could impact the feasibility of in-space drug processing. The presented work demonstrates the successful recovery of the metastable Form III of ritonavir generated in orbit. The test samples and passive controls containing each of the anhydrous forms of ritonavir; Form I, Form II, Form III, and amorphous exhibit excellent stability. By providing a detailed experimental dataset centered on survivability, we pave the way for the future of in-space processing of medicines that enable the development of novel drug products on Earth and benefit long-duration human exploration initiatives.
More research is likely required, but I suspect Varda will be able to raise investment capital from this success, since there is a lot of money to be made from pharmaceuticals that can only be produced in weightlessness.
On March 20, 2024 Varda released the results from its seven-month-long flight of its unmanned capsule, claiming that the technology worked to produce pharmaceuticals in weightlessness that will be better at treating some difficult illnesses such as HIV.
From the abstract of the preprint paper [pdf]:
Despite notable progress in realizing the benefits of microgravity, the physical stability of therapeutics processed in space has not been sufficiently investigated. Environmental factors including vibration, acceleration, radiation, and temperature, if not addressed could impact the feasibility of in-space drug processing. The presented work demonstrates the successful recovery of the metastable Form III of ritonavir generated in orbit. The test samples and passive controls containing each of the anhydrous forms of ritonavir; Form I, Form II, Form III, and amorphous exhibit excellent stability. By providing a detailed experimental dataset centered on survivability, we pave the way for the future of in-space processing of medicines that enable the development of novel drug products on Earth and benefit long-duration human exploration initiatives.
More research is likely required, but I suspect Varda will be able to raise investment capital from this success, since there is a lot of money to be made from pharmaceuticals that can only be produced in weightlessness.